Better Incentives Needed For Worsening Fungal Infection Threat

The increasing threat of treatment-resistant Candida auris fungal infections suggests the need for greater development incentives, CEOs of three antifungal drug developers told the recent BIO annual meeting.

Fungi-Candida_608236289_1200x675

As companies seek new ways to address the rising threat of treatment-resistant Candida auris infections, they are calling for additional development incentives, such as R&D tax credits, that can spur investment in the space.

During a panel at the 2017 BIO International Convention, Tom Chiller, associate director for epidemiologic science at the Centers for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category